252-day price high (breakout)
ActiveAdjusted close makes a new 252-day high; repeats within 20 days counted once.
120 days after: historical avg +32%
Over 7 occurrences, 120-day forward avg gained 32%, beat the market by 26.79 pts; win rate 71.4%.
Copy the prompt to get recent events, historical reactions, and a short research brief.
Tell your AI:
Help me set up FinLab and analyze 1342 八貫. Please read: https://finlab.finance/en/setup?stock=1342
strong quality, fair valuation.
Top-tier profitability.Operating margin beats ~84% of the market. Latest quarterly ROE ≈ 7.2%.
Valuation is neutral.PE is in the 43th market percentile; within its own history, PE is around the 84th percentile.
Foreign investors are net buying.Foreign 20-day net flow ≈ 4.8% of volume (net buy).
Strong revenue growth.Latest monthly revenue YoY ≈ 37.2%, above the 20% growth threshold.
Signals are active now.On the latest data, signals such as 252-day price high, Revenue YoY ≥ 20% are active — see the historical forward returns after each occurrence below.
Distribution to retail — bearish
Window from 2026-01-17 · Price +20% · branches to 2026-06-17· TDCC to 2026-06-12
Weak direction: big-holder share fell while retail share rose.
Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.
These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.
Adjusted close makes a new 252-day high; repeats within 20 days counted once.
120 days after: historical avg +32%
Over 7 occurrences, 120-day forward avg gained 32%, beat the market by 26.79 pts; win rate 71.4%.
Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).
120 days after: historical avg +10.14%
Over 22 occurrences, 120-day forward avg gained 10.14%, beat the market by 6.81 pts; win rate 59.1%.
Each day's PE is converted to its own-history percentile (as of that day), then we look at adjusted-close returns over the next 240 trading days by valuation regime.
| PE percentile band | Sample days | 240-day avg return | Median | Win rate | Avg excess (vs index) |
|---|---|---|---|---|---|
| 0-20 | 148 | 0% | -2.8% | 37.8% | -36.6% |
| 20-40 | 112 | -5.1% | -8.5% | 26.8% | -37.2% |
| 40-60 | 90 | -10.2% | -10.1% | 0% | -38.5% |
| 60-80 | 10 | Insufficient data | |||
| 80-100 You are here | 0 | Insufficient data | |||
Percentiles use an expanding own-history window (no look-ahead); forward return is 240 trading days on adjusted close. Sample days overlap; distribution is indicative only.
Current PE ≈ 19.58, at the 83.8th percentile of its own history (80-100 band).
Every day in its own history is bucketed by valuation tercile (own-history PE) and 60-day momentum sign into six cells; we show adjusted-close returns over the next 120 trading days per cell.
Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.
Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.
Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.
These are not occurring now; historical samples shown for comparison.
Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.
19 times historically; 60-day forward avg +4.49%, win rate 52.9%, beating the market by +1.36 pts on average.
八貫股份有限公司(英文簡稱CCI Yilan,公司英文名Cathay Consolidated, Inc.),成立於1982年(民國71年)6月,原為有限公司,2007年12月(民國96年)改制為股份有限公司,2020年11月24日於台灣證券交易所掛牌上市。總部與生產基地位於宜蘭縣冬山鄉德興四路6號。實收資本額約新台幣7.8億元(股本約7.9億元)。董事長兼總經理為劉宗熹(此一人事資訊僅單一來源,信心度中等)。公司早期(1982年起)從事進出口貿易,2008年後策略轉型為製造業,專注以TPU(熱塑性聚氨酯)機能性皮布料替代傳統PVC製品。員工人數、主要股東與法人持股明細未能於本次研究中取得可靠數據。
主營TPU(熱塑性聚氨酯彈性體)機能性皮布料及成品組件之二次、三次加工製造與銷售。依產品型態分為兩大事業群:(1)皮布料事業群(約佔營收65%),生產機能性皮布料及TPU薄膜;(2)成品組件事業群(約佔35%),運用自家布料/薄膜製作成品與半成品。若依終端市場別(2023上半年概況)約為:戶外產品約54%、醫療產品約21%、航太救生約13%、工業及軍工約12%(此比重隨期間與訂單而變動)。產品終端應用涵蓋運動鞋材、3C電子、汽車內飾、電纜、露營睡墊與枕頭、防水收納/蓄水袋、潛水浮力裝置、救生衣/救生筏、加護病床與居家長照床墊、醫療管材、飛機逃生滑梯,以及軍工防彈背心材料、軍用油箱等。商業模式為承接國際品牌客戶之利基型、客製化機能材料與組件代工(訴求高性能、防水透濕、環保替代PVC)。
2024年全年營收約25.1億元(12月單月創高約2.8億元);市場與分析文章估2025年營收約27.8億元、EPS約7.13元(年增約11.76%,屬分析師預估非公司正式財測)。2026年1~5月累計營收約16.04億元、年增約26.65%,Q1 EPS約2.08元,毛利率約27%、營益率約20%。三大成長動能:(1)軍工——新型防彈背心完成認證並量產出貨,標案能見度延伸至2025年中,2024年軍工單季一度年增約302%;(2)醫療——與Hillrom、Arjo、Stryker等合作,聚焦高附加價值醫療床墊與居家照護,估年增約20%;(3)航太救生——供應鏈緩解、輕量化逃生滑梯放量,市佔由約20%提升至30~35%。產能方面已完成德興一路二期擴廠(新增約23,701平方米),醫療床墊/露營睡墊月產能增至約35,000件(+34.6%)、醫療管材月產能增至約350,000件(+45.8%),新增約74台高週波機等設備;並導入更輕耐用之TPU材料與TPU噴霧新技術。潛在風險:上游原料供應商高度集中(BASF、Lubrizol、Covestro)、戶外消費受景氣循環影響、無人機等新型戰爭型態可能改變軍工需求結構、匯率波動、終端客戶庫存調整。2027~2028年缺乏明確公開財測,本欄2025年後數字多屬分析估算,請審慎參考。
This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.
This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.